logo
Parts of T.N. face shortage of HIV test kits; mechanism sought to address issue

Parts of T.N. face shortage of HIV test kits; mechanism sought to address issue

The Hindu06-05-2025

As in previous years, some parts of Tamil Nadu are yet again facing a shortage of HIV test kits.
Over the past few months, government doctors and health staff have been raising concerns over the non-availability of adequate test kits.
Sources said that while there were supply disruptions from the National AIDS Control Organisation (NACO), Tamil Nadu, despite past experience, failed to put in place a mechanism to address the issue.
Focused testing
'The primary objective is focused testing of high-risk groups and antenatal women. The ultimate goal is to screen the general population for HIV and sexually transmitted infections. So, we can meet the testing needs of high-risk groups through NACO's supply; and the State Health Department, along with Tamil Nadu State AIDS Control Society (TANSACS), should put in place a mechanism to ensure availability of kits for the general population,' an official source said.
With an adult HIV/AIDS prevalence of 0.20% (among people aged 15 to 49), Tamil Nadu needs to have some guidelines or a mechanism in place to address this issue, instead of instructing districts to manage it through local purchases that could raise quality concerns, another source said.
A health staff in a western district said they were told to use the available test kits only for high-risk groups. A doctor in a northern district said pregnant women were mandatorily tested for HIV/AIDS at Primary Health Centres (PHC), and their spouses were also tested for HIV/AIDS and venereal diseases along with blood grouping.
'Now, due to a shortage of kits, tests are done only for pregnant women in PHCs, and their spouses are referred to the government hospitals. We were told that oral instructions had been issued to the chief medical officers of the GHs to procure the required kits using the Chief Minister's Comprehensive Health Insurance Scheme funds or make local purchases due to the shortage of kits,' he said.
Doctors said the available kits were being used only for antenatal women and high-risk groups, and government hospitals and government medical college hospitals had been told to procure kits on their own for screening before surgeries.
Another government doctor said the District AIDS Prevention and Control Unit provided dual-test kits for screening antenatal women.
'The most affected are government hospitals and government medical college hospitals. The reason is we screen patients who are taken up for general and orthopaedic surgeries. Now, if hospital administrators do not get kits through CMCHIS funds, surgeries could be performed without screening, thereby putting the surgical team at risk. This shortage surfaces now and then, and some hospitals have already spent a significant amount from the CMCHIS fund to procure kits to screen spouses of pregnant women and those undergoing surgeries. In fact, contact tracing (of those who test positive) has been left in the lurch for almost six months in some places,' he said.
Despite attempts to reach TANSACS officials for comment, there was no response.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Upgrade GEMCH in Perundurai into multi super speciality hospital: AITUC
Upgrade GEMCH in Perundurai into multi super speciality hospital: AITUC

The Hindu

time11 hours ago

  • The Hindu

Upgrade GEMCH in Perundurai into multi super speciality hospital: AITUC

The All India Trade Union Congress (AITUC) has urged the State government to upgrade the Government Erode Medical College and Hospital (GEMCH) in Perundurai into a multi super speciality hospital to enhance healthcare facilities in the region. A memorandum in this regard was prepared by AITUC's Erode district president S. Chinnasamy and was recommended and submitted by Tiruppur MP and AITUC All India vice-president K. Subbarayan to Health Minister Ma. Subramanian during his visit to the hospital on Friday. According to the memorandum, the Ramalingam Tuberculosis Sanatorium (RTS), located in Sanitorium, Perundurai, was established in 1939. In 1992, it was converted into a medical college and hospital under the Tamil Nadu State Transport Corporation (IRT–PMCH). Later, in 2018, it was taken over by the Government of Tamil Nadu, and since 2020, it has been functioning as the GEMCH. Currently, the hospital lacks facilities for treatment of various ailments, including cardiology, nephrology, neurology, oncology, and plastic surgery. As a result, patients are compelled to travel nearly 80 km to Coimbatore or Salem for treatment, causing severe hardship. Therefore, the memorandum strongly urged the government to upgrade the hospital into a full-fledged multi super speciality facility with comprehensive infrastructure. With the long-standing demand for an All India Institute of Medical Sciences (AIIMS) in the region still unmet, the upgrade was described as all the more critical. The memorandum also called for upgrading the Government Hospital in Perundurai town to at least a 60-bed facility. Additionally, it sought the elevation of the upgraded Government Primary Health Centres in Chennimalai and Thingalur into full-fledged government hospitals. It also requested the establishment of new Government Primary Health Centres in Pandiyampalayam and Ingur villages.

Know the truth: Common myths about cervical cancer explained
Know the truth: Common myths about cervical cancer explained

India Today

time12 hours ago

  • India Today

Know the truth: Common myths about cervical cancer explained

According to Globocon 2020, cervical cancer is the 4th most common cancer amongst women globally. India alone accounts for one-quarter of the global burden, with an estimated 1,23,907 new cases and 77,348 deaths Today spoke with Dr Pratima Raj, Associate Consultant – Gynaecological Oncology, Manipal Hospital Old Airport gain insights on the most common misconceptions surrounding cervical cancer and why awareness is key to early detection and considerable awareness campaigns and media attention on cervical cancer and HPV vaccination, the topic remains riddled with misinformation. Myths persist around screening, vaccines, and HPV itself, often preventing timely intervention. With the right information, however, cervical cancer is largely preventable and HPV ONLY AFFECTS PROMISCUOUS WOMEN Fact: HPV can affect any sexually active woman. Even one sexual partner is enough to contract HPV. Studies reveal that over 80 percent of women will acquire HPV by age HAVING HPV MEANS YOU'LL GET CERVICAL CANCERFact: While HPV is common, most infections resolve on their own. Only persistent high-risk strains can lead to cancerous changes. Regular screening helps detect these HPV INFECTIONS HAVE SYMPTOMSFact: Most HPV infections are asymptomatic. High-risk strains often go unnoticed unless caught through Pap smears or HPV symptoms of cervical cancer (if present) include abnormal discharge, irregular or heavy bleeding, post-coital bleeding, and pelvic or abdominal SCREENING IS THE ONLY PREVENTIVE MEASUREadvertisementFact: In addition to Pap tests and HPV testing, lifestyle factors play a role. Avoiding smoking, delaying sexual activity, and limiting partners can reduce risk. Other risk factors include chlamydia or HIV infections and weakened VACCINATED WOMEN DON'T NEED PAP TESTSFact: The HPV vaccine doesn't protect against all cancer-causing strains. Even vaccinated women should continue regular Pap and HPV PAP TESTS ARE NEEDED ANNUALLYFact: Current guidelines recommend:Ages 21–29: Pap test every 3 yearsAges 30–65: Pap + HPV co-test every 5 years65 and older: screening may stop if past tests were normalMYTH: HPV CLEARS ON ITS OWNFact: While some infections resolve naturally, others persist and can lead to genital warts or monitoring is CERVICAL CANCER ENDS FERTILITYFact: Fertility-preserving treatments are now available for early-stage cases.A hysterectomy is not always CERVICAL CANCER IS HEREDITARYFact: Cervical cancer is caused by HPV, not inherited like breast or ovarian and screening remain the best ONLY WOMEN WITH MULTIPLE PARTNERS ARE AT RISKFact: Even one sexual encounter can expose someone to is a sexually transmitted infection, not a moral LONG GAPS IN SEXUAL ACTIVITY ELIMINATE RISKadvertisementFact: Cervical cancer can develop long after infection, regardless of recent sexual PAP TESTS DETECT OVARIAN OR UTERINE CANCERFact: Cervical screening only checks the does not detect cancers of the uterus, ovaries, or fallopian HPV VACCINES ARE ONLY FOR TEENAGERSFact: The vaccine is most effective before sexual activity, but still beneficial for those already sexually ONLY WOMEN SHOULD WORRY ABOUT HPVFact: All genders are vulnerable to is recommended for ages 9– CONDOMS FULLY PREVENT HPVFact: Condoms reduce but don't eliminate the risk due to skin-to-skin CERVICAL CANCER IS ALWAYS FATALFact: When detected early, treatment is highly effective, and survival rates are OLDER WOMEN ARE NOT AT RISK OF HPVFact: HPV can affect anyone, regardless of THERE'S NO CURE FOR CERVICAL CANCERSurgery, chemotherapy, and radiation therapy can be curative, especially in early stages. Cervical cancer is one of the few cancers that is largely preventable and highly treatable when detected vaccination, regular screening, and healthy lifestyle choices, women (and all who are at risk) can dramatically reduce their chances of developing this disease. Armed with facts rather than fears, every woman can take charge of her reproductive health and help ensure that cervical cancer becomes a chapter of the past, not the Reel

Can This Covid Vaccine Technology Also 'Kick And Kill' HIV?
Can This Covid Vaccine Technology Also 'Kick And Kill' HIV?

News18

timea day ago

  • News18

Can This Covid Vaccine Technology Also 'Kick And Kill' HIV?

Last Updated: A team of Australian scientists has developed a novel method to reveal hidden HIV in white blood cells Scientists at Australia's Peter Doherty Institute for Infection and Immunity in Melbourne have developed a groundbreaking method to 'wake up" hidden HIV within the human body, a crucial step that could enable their complete removal. And they have used mRNA technology, the same kind used in Pfizer and Moderna's Covid-19 vaccines. Nearly 40 million people are living with HIV worldwide. One of the main challenges in curing the human immunodeficiency virus (HIV) lies in its ability to establish latent reservoirs. These are small numbers of infected cells, primarily resting CD4+ T cells, where the virus integrates its genome but remains dormant and invisible to both the immune system and antiretroviral therapies (ART). While ART can suppress the virus to undetectable levels, it cannot eliminate these hidden reservoirs. If treatment stops, the virus can re-emerge and replicate, necessitating lifelong medication for people living with HIV. The Australian team discovered a novel way to deliver 'special instructions" to these hidden, latently infected cells. In a study published in Nature Communications, the researchers demonstrated how they packaged mRNA inside novel, microscopic fat-like bubbles called lipid nanoparticles (LNPs), specifically a new design termed 'LNP X". The key breakthrough was engineering these LNPs to successfully transport the mRNA into the previously hard-to-reach resting CD4+ T cells. Once delivered, the mRNA instructs these cells to 'give up" the dormant virus, forcing it out of hiding and making it visible. This strategy aligns with the long-sought 'kick and kill" approach to HIV cure, where latency-reversing agents 'shock" the virus out of its dormant state, allowing the body's immune system or other therapies to 'kill" the newly exposed infected cells. Dr Paula Cevaal, a research fellow at the Doherty Institute and co-first author, described the initial results as astonishing, requiring repeated experiments to confirm their accuracy. 'We were overwhelmed by how big the difference was," she noted, emphasising the unprecedented success in revealing the hidden virus. While the research is currently laboratory-based and conducted on cells donated by HIV patients, this innovative method represents a significant step forward. The next crucial phase involves preclinical testing in animal models, followed by human trials to assess safety and efficacy. First Published: June 07, 2025, 04:36 IST

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store